Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $8.74 USD
Change Today +0.01 / 0.11%
Volume 414.3K
INFI On Other Exchanges
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

infinity pharmaceuticals inc (INFI) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/12/14 - $18.25
52 Week Low
07/27/15 - $8.42
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

infinity pharmaceuticals inc (INFI) Related Businessweek News

No Related Businessweek News Found

infinity pharmaceuticals inc (INFI) Details

Infinity Pharmaceuticals, Inc., a drug discovery and development company, discovers, develops, and delivers medicines to patients with difficult-to-treat diseases. Its lead product candidate includes IPI-145, an oral inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) for the treatment of hematologic malignancies. The company is developing DYNAMO, which is in Phase II study to evaluate the safety and efficacy of IPI-145 dosed at 25 mg; DYNAMO+R that is in Phase III randomized study to evaluate IPI-145 dosed at 25 mg in combination with rituximab, a monoclonal antibody treatment; and DUO, which is in randomized Phase III monotherapy study evaluating IPI-145 dosed at 25 mg in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). It is also conducting a Phase Ib trial of IPI-145 in combination with obinutuzumab, a monoclonal antibody treatment in CLL patients; a Phase Ib/II clinical study of IPI-145 in combination with obinutuzumab or rituximab in patients with untreated follicular lymphoma; and an ongoing Phase I dose-escalation study to evaluate the safety, pharmacokinetics, and clinical activity of IPI-145 in patients with advanced hematologic malignancies. The company has collaboration and license agreement with AbbVie Inc. to develop and commercialize IPI-145 in oncology; and development and license agreement with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

195 Employees
Last Reported Date: 02/24/15

infinity pharmaceuticals inc (INFI) Top Compensated Officers

Chairman of The Board, Chief Executive Office...
Total Annual Compensation: $568.5K
Chief Financial Officer, Chief Business Offic...
Total Annual Compensation: $390.0K
President of Research & Development
Total Annual Compensation: $479.5K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $647.1K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $381.0K
Compensation as of Fiscal Year 2014.

infinity pharmaceuticals inc (INFI) Key Developments

Infinity Pharmaceuticals, Inc. Presents at BMO Capital Markets Biotech Corporate Access Day, Jul-28-2015

Infinity Pharmaceuticals, Inc. Presents at BMO Capital Markets Biotech Corporate Access Day, Jul-28-2015 . Venue: Boston, Massachusetts, United States.

Infinity Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2015

Infinity Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2015., at 08:30 US Eastern Standard Time. Location: 784 Memorial Drive.

Infinity Pharmaceuticals, Inc. Announces New Clinical Data for Duvelisib

Infinity Pharmaceuticals, Inc. announced new clinical data for duvelisib (IPI-145), an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma in patients with treatment-naïve chronic lymphocytic leukemia (CLL), a potentially fatal hematologic malignancy (blood cancer). Data from the Phase 1 study showed that duvelisib was highly active in this patient population cohort, with an overall response rate of 88% as defined by the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria, including 15 partial responses among 17 efficacy evaluable patients. These data will be presented at the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. on Sunday, May 31, 2015. The company also announced new translational data demonstrating that treatment with duvelisib resulted in a decrease in key mediators known to be involved in the communication between CLL cells and the tumor microenvironment. These data further support the investigation of dual inhibition of PI3K-delta and PI3K-gamma with duvelisib as a therapeutic strategy for the treatment of CLL.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INFI:US $8.74 USD +0.01

INFI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CTI BioPharma Corp $1.85 USD +0.005
Curis Inc $3.14 USD -0.06
Cytokinetics Inc $6.39 USD +0.30
Evotec AG €3.38 EUR -0.029
GlaxoSmithKline SAE £11.50 EGP 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation INFI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.5x
Price/Book 3.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INFINITY PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at